Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome
Top Cited Papers
Open Access
- 30 January 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (5), 508-518
- https://doi.org/10.1111/j.1365-2036.2008.03911.x
Abstract
Background Gut microflora‐mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). Aim To investigate the efficacy of a novel prebiotic trans‐galactooligosaccharide in changing the colonic microflora and improve the symptoms in IBS sufferers. Methods In all, 44 patients with Rome II positive IBS completed a 12‐week single centre parallel crossover controlled clinical trial. Patients were randomized to receive either 3.5 g/d prebiotic, 7 g/d prebiotic or 7 g/d placebo. IBS symptoms were monitored weekly and scored according to a 7‐point Likert scale. Changes in faecal microflora, stool frequency and form (Bristol stool scale) subjective global assessment (SGA), anxiety and depression and QOL scores were also monitored. Results The prebiotic significantly enhanced faecal bifidobacteria (3.5 g/d P < 0.005; 7 g/d P < 0.001). Placebo was without effect on the clinical parameters monitored, while the prebiotic at 3.5 g/d significantly changed stool consistency (P < 0.05), improved flatulence (P < 0.05) bloating (P < 0.05), composite score of symptoms (P < 0.05) and SGA (P < 0.05). The prebiotic at 7 g/d significantly improved SGA (P < 0.05) and anxiety scores (P < 0.05). Conclusion The galactooligosaccharide acted as a prebiotic in specifically stimulating gut bifidobacteria in IBS patients and is effective in alleviating symptoms. These findings suggest that the prebiotic has potential as a therapeutic agent in IBS.Keywords
This publication has 40 references indexed in Scilit:
- Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trialAlimentary Pharmacology & Therapeutics, 2007
- Functional Bowel DisordersGastroenterology, 2006
- Management of irritable bowel syndromeEuropean Journal of Gastroenterology & Hepatology, 2003
- A 16S rRNA-targeted Probe for Detection of Lactobacilli and Enterococci in Faecal Samples by FluorescentIn SituHybridizationMicrobial Ecology in Health & Disease, 1999
- The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disordersGastroenterology, 1996
- Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-flavobacter-bacteroides in the natural environmentMicrobiology, 1996
- Irritable bowel-type symptoms in HMO examineesDigestive Diseases and Sciences, 1993
- Irritable bowel syndrome in the general population.BMJ, 1992
- Instability in the faecal flora of a patient suffering from food-related irritable bowel syndromeJournal of Medical Microbiology, 1987
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983